HFA-PEFF score: prognosis in patients with preserved ejection fraction after transcatheter aortic valve implantation.

Aortic stenosis Heart failure Mortality Preserved ejection fraction Rehospitalization Transcatheter aortic valve implantation

Journal

ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191

Informations de publication

Date de publication:
04 2022
Historique:
revised: 31 10 2021
received: 24 06 2021
accepted: 02 12 2021
pubmed: 30 1 2022
medline: 26 3 2022
entrez: 29 1 2022
Statut: ppublish

Résumé

Many transcatheter aortic valve implantation (TAVI) candidates have underlying heart failure with preserved ejection fraction (HFpEF) in addition to symptomatic aortic stenosis. Diagnosis of HFpEF is challenging. The Heart Failure Association of the European Society of Cardiology proposed the HFA-PEFF score as part of a novel diagnostic algorithm. This study assessed the prognostic value of the HFA-PEFF score in patients with preserved ejection fraction after TAVI. This single-centre study included 570 consecutive TAVI patients with a preserved left ventricular ejection fraction of ≥50%. Patients with an HFA-PEFF score of ≥5 [n = 239 (41.9%)] were compared with those with <5 points [n = 331 (58.1%)]. The primary outcome was a composite of all-cause mortality or first heart failure rehospitalization within 1 year after TAVI. Secondary endpoints were the individual components of the primary outcome. Patients with an HFA-PEFF score ≥ 5 had higher rates of comorbidities commonly associated with HFpEF, a higher rate of new pacemaker implantation after TAVI, were at increased risk of the primary composite endpoint (25.5% vs. 10.0%, P < 0.001), and rehospitalization for heart failure (11.7% vs. 3.9%, P < 0.001). Multivariable analysis confirmed an HFA-PEFF score ≥ 5 as an independent risk factor for the composite endpoint [hazard ratio 2.70, 95% confidence interval (CI) 1.70-4.28, P < 0.001] and for all-cause mortality (hazard ratio 2.58, 95% CI 1.46-4.53, P = 0.001). The HFA-PEFF score is associated with all-cause mortality and heart failure rehospitalization in patients with preserved ejection fraction after TAVI. This practical tool can easily be incorporated into risk stratification algorithms for TAVI patients.

Identifiants

pubmed: 35092186
doi: 10.1002/ehf2.13774
pmc: PMC8934930
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1071-1079

Informations de copyright

© 2022 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

Références

J Cardiovasc Magn Reson. 2020 Jun 1;22(1):41
pubmed: 32475350
Heart. 2017 Oct;103(19):1481-1487
pubmed: 28684437
Eur J Heart Fail. 2016 Jul;18(7):744-58
pubmed: 27358242
JACC Cardiovasc Imaging. 2020 Feb;13(2 Pt 1):481-493
pubmed: 31202751
J Am Coll Cardiol. 2010 Jun 1;55(22):2491-8
pubmed: 20510217
Eur Heart J. 2003 Jul;24(13):1231-43
pubmed: 12831818
ESC Heart Fail. 2022 Apr;9(2):1071-1079
pubmed: 35092186
Am J Cardiol. 2020 Jan 15;125(2):251-257
pubmed: 31759517
Eur J Heart Fail. 2020 Mar;22(3):413-421
pubmed: 31472035
N Engl J Med. 2021 Oct 14;385(16):1451-1461
pubmed: 34449189
ESC Heart Fail. 2021 Jun;8(3):2089-2102
pubmed: 33709628
ESC Heart Fail. 2021 Jun;8(3):2154-2164
pubmed: 33760383
Eur Heart J. 2018 May 21;39(20):1770-1780
pubmed: 29390051
Eur Heart J. 2019 Oct 21;40(40):3297-3317
pubmed: 31504452
Circulation. 2018 Aug 28;138(9):861-870
pubmed: 29792299
JACC Heart Fail. 2020 Aug;8(8):640-653
pubmed: 32535127
Nat Rev Dis Primers. 2016 Mar 03;2:16006
pubmed: 27188578
J Am Heart Assoc. 2017 Jul 11;6(7):
pubmed: 28698259
Eur J Heart Fail. 2021 Jun;23(6):954-963
pubmed: 33634544
Front Cardiovasc Med. 2021 Jun 10;8:665424
pubmed: 34179132
PLoS One. 2019 Nov 26;14(11):e0225473
pubmed: 31770401
ESC Heart Fail. 2021 Feb;8(1):461-470
pubmed: 33215870
Eur Heart J. 2012 Jul;33(14):1750-7
pubmed: 21821849
Circ J. 2021 Apr 23;85(5):604-611
pubmed: 33250499
Eur Heart J. 2017 Sep 21;38(36):2739-2791
pubmed: 28886619
Eur Heart J. 2021 May 14;42(19):1825-1857
pubmed: 33871579
PLoS One. 2018 Aug 22;13(8):e0202733
pubmed: 30133531
Circulation. 2014 Jun 24;129(25):2682-90
pubmed: 24958751
J Am Coll Cardiol. 2013 Sep 10;62(11):1002-12
pubmed: 23727214

Auteurs

Hatim Seoudy (H)

Department of Internal Medicine III, Cardiology and Angiology, University Hospital Schleswig-Holstein, Campus Kiel, Arnold-Heller-Str.3, Haus K3, Kiel, 24105, Germany.
DZHK (German Centre for Cardiovascular Research), partner site Hamburg/Kiel/Lübeck, Kiel, Germany.

Mira von Eberstein (M)

Department of Internal Medicine III, Cardiology and Angiology, University Hospital Schleswig-Holstein, Campus Kiel, Arnold-Heller-Str.3, Haus K3, Kiel, 24105, Germany.

Johanne Frank (J)

Department of Internal Medicine III, Cardiology and Angiology, University Hospital Schleswig-Holstein, Campus Kiel, Arnold-Heller-Str.3, Haus K3, Kiel, 24105, Germany.
DZHK (German Centre for Cardiovascular Research), partner site Hamburg/Kiel/Lübeck, Kiel, Germany.

Maren Thomann (M)

Department of Internal Medicine III, Cardiology and Angiology, University Hospital Schleswig-Holstein, Campus Kiel, Arnold-Heller-Str.3, Haus K3, Kiel, 24105, Germany.

Thomas Puehler (T)

DZHK (German Centre for Cardiovascular Research), partner site Hamburg/Kiel/Lübeck, Kiel, Germany.
Department of Cardiac and Vascular Surgery, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.

Georg Lutter (G)

DZHK (German Centre for Cardiovascular Research), partner site Hamburg/Kiel/Lübeck, Kiel, Germany.
Department of Cardiac and Vascular Surgery, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.

Matthias Lutz (M)

Department of Internal Medicine III, Cardiology and Angiology, University Hospital Schleswig-Holstein, Campus Kiel, Arnold-Heller-Str.3, Haus K3, Kiel, 24105, Germany.
DZHK (German Centre for Cardiovascular Research), partner site Hamburg/Kiel/Lübeck, Kiel, Germany.

Peter Bramlage (P)

Institute for Pharmacology and Preventive Medicine, Cloppenburg, Germany.

Norbert Frey (N)

Department of Cardiology, Angiology and Pneumology, Heidelberg University Hospital, Heidelberg, Germany.
DZHK (German Centre for Cardiovascular Research), partner site Heidelberg/Mannheim, Heidelberg, Germany.

Mohammed Saad (M)

Department of Internal Medicine III, Cardiology and Angiology, University Hospital Schleswig-Holstein, Campus Kiel, Arnold-Heller-Str.3, Haus K3, Kiel, 24105, Germany.

Derk Frank (D)

Department of Internal Medicine III, Cardiology and Angiology, University Hospital Schleswig-Holstein, Campus Kiel, Arnold-Heller-Str.3, Haus K3, Kiel, 24105, Germany.
DZHK (German Centre for Cardiovascular Research), partner site Hamburg/Kiel/Lübeck, Kiel, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH